NCT05476094View on ClinicalTrials.gov

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

August 16, 2023

Study Completion Date

August 23, 2023

Conditions
Healthy SubjectsSubmental Fat
Interventions
DRUG

Polyene Phosphatidylcholine

AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Gyeonggi-do

All Listed Sponsors
lead

AMIpharm Co., Ltd.

INDUSTRY